OncoMatch

OncoMatch/Clinical Trials/NCT05722288

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

Is NCT05722288 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for localized prostate carcinoma.

Phase 2RecruitingCity of Hope Medical CenterNCT05722288Data as of May 2026

This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among patients with prostate, cervical, and rectal cancers. Time-restricted eating, also called short term fasting or intermittent fasting, is an eating plan that alternates between not eating food (fasting) and non-fasting periods. Nutritional counseling involves being asked to follow a healthy, balanced diet that includes instructions on what kinds of food are better tolerated during radiation and chemoradiation therapy. This trial may help researchers determine if certain diets may improve the anti-cancer effects of radiation therapy and reduce the side-effects of this treatment. If successful, these diets may be integrated into the future treatment of prostate, cervical, and rectal cancers.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Cervical Cancer

Colorectal Cancer

Tumor Agnostic

Disease stage

Required: Stage I, II, IIIA, IIIB, IIIC, IVA, IB, IIA, IIB (AJCC v8 (prostate, rectal), FIGO 2018 (cervical))

Official conditions: ... Stage I Prostate Cancer AJCC v8; Stage IB Cervical Cancer FIGO 2018; Stage IB2 Cervical Cancer FIGO 2018; Stage II Prostate Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage IIA Cervical Cancer FIGO 2018; Stage IIB Cervical Cancer FIGO 2018; Stage III Prostate Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC Cervical Cancer FIGO 2018; Stage IVA Prostate Cancer AJCC v8

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: radiation therapy

PROSTATE CANCER: Prior radiation therapy to the prostate gland or pelvis

Cannot have received: androgen deprivation therapy

Exception: allowed if ≤ 6 months

PROSTATE CANCER: Prior therapy with androgen deprivation therapy for longer than 6 months

Cannot have received: chemotherapy

PROSTATE CANCER: Prior chemotherapy

Cannot have received: docetaxel (docetaxel)

PROSTATE CANCER: Men whose treatment plan includes up-front docetaxel will be excluded due potential confounding

Cannot have received: radiation therapy

GYNECOLOGIC CANCER: Prior radiation therapy to the cervix, uterus or pelvis

Cannot have received: chemotherapy

GYNECOLOGIC CANCER: Prior chemotherapy

Cannot have received: radiation therapy

RECTAL CANCER: Prior pelvic radiation therapy

Cannot have received: chemotherapy

RECTAL CANCER: Prior chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope Medical Center · Duarte, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify